AWARDDEFINITIVE CONTRACTSmall business
Definitive contract 75N93023C00055ABVIRO LLC
Overview
Award facts
- Net obligations
- $11.34M
- $11,335,102of $12.36M potential value
- Outlays (paid to date)
- $7.98M
- $7.98M paid of $11.34M obligated$7,978,461
- Period of performance
- Sep 25, 2023 to Dec 31, 2026
- Ends in 1 month
- Modifications
- 7
- Latest action Mar 24, 2026
- Contract type
- Definitive contract
- PIID 75N93023C00055
Contract value is the most the government could spend; obligations are what it has legally committed; outlays are what it has actually paid.
Description of requirement
TO CONDUCT A PHASE 2 DENGUE HUMAN CHALLENGE CLINICAL TRIAL OF ABVIRO ANTI-DENGUE MONOCLONAL ANTIBODY (MAB) AV-1.
Dates and value
- Award date
- Signed on Sep 21, 2023
- Potential end of performance
- Dec 30, 2026
- Current value
- $11,335,102Base and exercised options
- Potential value (if all options are exercised)
- $12,356,811
Obligations by fiscal year of action
- FY2026: $2,591,663
- FY2024: $6,990,472
- FY2023: $1,752,967
Total across 3 fiscal years: $11,335,102
Source: Federal Procurement Data System contract actions as published by SAM.gov and USAspending.gov; latest action recorded Mar 24, 2026. View on USAspending · Recipient on SAM.gov
Recipient
NameABVIRO LLC
LocationBETHESDA, MD
UEIK3L6KXJ9B6M7
CAGE code75YF3
Business sizeSmall businessSize at award, per the contracting officer
Organization typePartnership
Parent companyABVIRO LLC
Business types and certifications
For-profit organizationLimited liability companyPartnership or LLP
As represented in SAM.gov at the time of the action.
Subcontracting network
The prime, the subcontractors on this award, and their own subcontractors.
Agency and place
Awarding and funding
- Awarded by
- Department of Health and Human Services
- National Institutes Of Health
- NATIONAL INSTITUTES OF HEALTH NIAID
- Funded by
- Department of Health and Human Services
- National Institutes Of Health
- NATIONAL INSTITUTES OF HEALTH NIAID
- Funded from
- National institute of allergy and infectious diseases (0885)Program activities075-0885Federal accounts (agency financial reports)
Place of performance
- Place of performance
- Bethesda, Montgomery County, Maryland 20814-2934
- Congressional district (place of performance)
- MD-08As reported at the time of the action
Classification and competition
Classification
- Product or service (PSC)
- AN12HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH (research and development)
Competition
- Extent competed
- Full and open competitionA
- Solicitation procedures
- Negotiated proposal/quoteNP
- Set-aside
- No set-aside used
- Contract pricing
- Cost plus fixed feeU
- Offers received
- 31
Solicitation and notices
- Solicitation ID
- HHS-NIH-NIAID-BAA2022-1
- Solicitation date
- Jan 18, 2022
- Notices
- Award Notice posted Sep 26, 2023
- Award Notice posted May 1, 2023
- Award Notice posted May 1, 2023
- Solicitation posted Apr 8, 2022
- Solicitation posted Mar 16, 2022
- Solicitation posted Feb 17, 2022
- Solicitation posted Feb 14, 2022
- Solicitation posted Jan 18, 2022
- Presolicitation posted Jan 4, 2022
Contract details
- Subcontracting plan
- Plan not requiredB
- Cost Accounting Standards clause
- Not applicable exempt from CASX
- Certified cost or pricing data
- Yes
- Commercial procedures
- Commercial products/services procedures not usedD
- Government-furnished property
- Transaction does not use GFE/GFPN
- Bundled requirement
- Not bundledH
- Consolidated requirement
- Not consolidatedD
- Undefinitized action (terms not final)
- No
- Multi-year contract
- No
- Performance-based service acquisition
- No - service where PBA is not used.N
Linked notices
Notice | Notice ID | Type | Link | Posted |
|---|---|---|---|---|
Transaction history
Modification history
- Base award
- Sep 21, 2023Base obligation at award: $1,752,967
- Latest action
- Mar 24, 2026 — Funding onlyModification P00007; obligation change +$2,591,663; funding only: changes obligations, not scope
- Latest substantive action
- Jul 1, 2024 — Option exercisedModification P00005; obligation change +$6,235,886
- Latest funding action
- Mar 24, 2026 — Funding onlyModification P00007; obligation change +$2,591,663; funding only: changes obligations, not scope
- Actions by type
- Base award1
- Other administrative action3
- Funding only2
- Change order1
- Option exercised1
Similar awards
PIID | Match | Awardee |
|---|---|---|
All contract data
All contract data
Every other field reported for this award, as of its latest reported action
Competition
- Evaluation preference
- No preference used
- Local area set-aside
- No
- Synopsized publicly (SAM.gov / FedBizOpps)
- Yes
- Simplified procedures for commercial items
- No
Pricing and financing
- Paid by purchase card
- No
- Latest action: change in base and exercised options
- $2,591,663
- Latest action: change in base and all options
- $2,591,663
Socio-economic and policy
- Inherently governmental functions
- Other functionsOT
- Recovered materials and sustainability
- No clauses included and no sustainability includedC
- EPA-designated product
- Not requiredE
- Clinger-Cohen Act planning (IT)
- No
Place and origin
- Domestic or foreign entity
- U.S. owned businessA
- Country of product or service origin
- United statesUSA
- Place of manufacture
- Not a manufactured end productC
Structure
- Award or IDV
- Award
- Award type
- Definitive contractD
- Awarding agency code
- 7500
- Awarding sub-tier code
- 7529
- Contracting office code
- 75N930
- Transactions recorded under this award key
- 8
Funding
- Funding agency code
- 7500
- Funding sub-tier code
- 7529
- Funding office code
- 75N930
- Treasury accounts
- 075-2023/2023-0885-000
- 075-2024/2024-0885-000
- Object classes
- 25.5: Research and development contracts
- Disaster or emergency funding (DEFC)
- Q: Not Designated Nonemergency/Emergency/Disaster/Wildfire Suppression